Director, Global Value & Access Strategy, povetacicept

Vertex Inc. • Boston, MA

1d • Hybrid

About The Position

Vertex operates at the forefront of scientific innovation and has successfully developed and commercialized multiple breakthrough medicines for Cystic Fibrosis (CF), Casgevy, a gene therapy for sickle cell disease and beta-thalassemia and Journavx, a novel new treatment for moderate to severe acute pain. Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases including programs in kidney diseases, Type 1 diabetes, among others. Povetacicept is a highly potent and effective dual antagonist of BAFF and APRIL pathways with potential best-in-class efficacy in patients with IgA nephropathy (IgAN). IgAN is a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. IgAN is the most common cause of primary (idiopathic) glomerulonephritis worldwide. Due to its mechanism of action as a dual BAFF/APRIL antagonist, povetacicept holds the potential to benefit patients for multiple additional serious diseases including other autoimmune kidney diseases and autoimmune cytopenias such as primary membranous nephropathy (pMN) and generalized myasthenia gravis (gMG). Vertex is expanding its Global Value and Access Strategy (GVAS) team to support commercialization of this exciting product. Market Access is a key commercial function that ensures transformative Vertex therapies are appropriately funded and ultimately make it into the hands of the patients around the world. GVAS works cross-functionally and across regions to ensure the payer view is represented in commercial and development plans across the lifecycle. We are driven by a desire to deliver groundbreaking pricing & reimbursement solutions to allow our medicines to reach patients faster than ever before. The Director, Global Value & Access Strategy, povetacicept role will support the asset with a primary focus on life cycle management (LCM). In this capacity, the individual will help to inform development of the povetacicept disease prioritization/portfolio strategy and ultimately the commercial strategy, to ensure price and access success. This individual will lead the assessment of price/access potential and key considerations such as indication/launch sequencing for these new indications in close collaboration with cross-functional and regional access colleagues. This role will also contribute to cross-portfolio capability building and thought leadership projects that advance knowledge of and readiness for the rapidly evolving Global payer environment. The role reports to Global Value & Access Strategy Lead, Kidney.

Requirements

• 8+ years of direct biotechnology / pharmaceutical industry experience and/or payer experience
• Deep working knowledge of both US and ex-US healthcare systems required, experience in comparable global and/or specialty disease area role considered a plus
• Demonstrated ability to think strategically and make sound pricing and market access recommendations
• Entrepreneurial, energetic, dynamic, enthusiastic, decisive, and self-motivated; possesses a sense of urgency with the ability and strong desire to "make things happen"
• Strong practical, quantitative and analytical skills combined with a sound understanding of how to successfully apply pricing & reimbursement / HEOR principles
• General experience in commercialization and drug development
• Demonstrated ability to effectively operate within highly cross-functional teams within a matrix environment
• Exhibits outstanding written and oral communication skills, including the ability to effectively write and deliver presentations to professionals at all levels within Vertex
• Demonstrated relationship building at all levels of the organization and across geographies
• Recognized as a team player with excellent interpersonal skills who is flexible and reliable
• Displays sound ethics and a fit for Vertex’s core values
• BA/BS in field of study requiring quantitative analysis; advanced degree preferred

Responsibilities

• Life-cycle management: Partner cross-functionally to shape LCM strategy, including overall valuation and prioritization of indications, implications on indication sequencing, pricing & market access optimization
• Identify, prioritize and champion evidence required for access enabling trials and value optimization; determine minimum reimbursable profiles
• Drive delivery of early, unbranded disease area value communications and supportive training, message platform
• Launch readiness for IgAN / launch planning for pMN and gMG indications: Support development of the global pricing and market access strategy and value communications to support global market access and value upon full approval for IgAN
• Drive delivery of the core message platform to inform development of the unbranded and branded value communications for pMN and gMG
• Contribute to development of market access strategies and core Global P&MA deliverables to support value and access optimization for pMN and gMG; includes development of the Global Payer Plans which integrate evidence generation priorities, strategic pricing, value communications and stakeholder engagement to optimize price and access
• Accountable for ensuring the market access and payer perspective is reflected in cross-functional strategies (e.g. commercial, product development, regulatory affairs)
• Collaborate closely with HEOR, regional market access, global commercial strategy, clinical development, medical affairs and corporate affairs counterparts to ensure value & access optimization
• Maintain industry awareness and proactively address changes in market trends, competition, product acceptance and new product releases and adjust market access plans accordingly

What This Job Offers

• Job Type: Full-time
• Career Level: Director